George Golumbeski
Partner @ Droia Ventures
Menlo Park, United States
George Golumbeski is a Series A investor at Droia Ventures in Menlo Park focused on Biotechnology and Medical. George Golumbeski is based out of New York, New York, and is the Partner of Droia Ventures and also the Member of the Board of Directors of Faron Pharmaceuticals. George previously worked at Celgene as an Executive Vice President of Business Development. George Golumbeski attended the University of Virginia.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries George Golumbeski invests in
Stages George Golumbeski invests in
Countries George Golumbeski invests in
Investment Focus
Industry
- Biotechnology 4 (80%)
- Medical 2 (40%)
- Life Science 2 (40%)
- Therapeutics 2 (40%)
- Genetics 1 (20%)
Stage
- Series A 3 (60%)
- Series B 1 (20%)
- Series D 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Actio Biosciences
|
Actio Biosciences involves in the development of precision medicines for homogenous rare patient populations. They develop a pipeline of new medicines with the goal to enhance the probability of clinical success and deliver medicines for all patients. | $66M / Series B / Jun 18, 2025 | |
Judo Bio
|
Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases. By leveraging its innovative receptor targeting approach, Judo Bio is developing a pipeline aimed at benefiting patients with both common and rare diseases. | $75M / Series A / Oct 07, 2024 | |
|
Actio Biosciences
|
Actio Biosciences involves in the development of precision medicines for homogenous rare patient populations. They develop a pipeline of new medicines with the goal to enhance the probability of clinical success and deliver medicines for all patients. | $55M / Series A / Sep 12, 2023 | |
Vicinitas Therapeutics
|
Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit. | $65M / Series A / Jul 28, 2022 | |
Acceleron Pharma
|
Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone formingagent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts. | Series D |
Co-Investors
About Droia Ventures
Droia is a specialist biotech investor with an exclusive focus on therapeutics for oncology and genetic disease. Droia invests globally in newly founded or early-stage platform companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. With our team of seasoned scientists, entrepreneurs, andinvestment professionals we build great companies to save patient lives.
Droia Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
George Golumbeski
Partner
|
|||
Luc Verelst
Founder & Chairman
|
|||
Thomas Martz
Entrepreneur-In-Residence
|
|||
Bart Van Hooland
Managing Partner
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does George Golumbeski invest in?
George Golumbeski invests primarily in Biotechnology, Medical and Life Science startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did George Golumbeski last invest?
The most recent investment recorded for George Golumbeski closed in Jun 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
